Back to top

Image: Bigstock

Monsanto (MON) Q1 Earnings Top, Revenues Miss Estimates

Read MoreHide Full Article

Monsanto Company has carved a name for itself in the global agricultural chemicals’ industry. The company tries to enhance the yield and quality of several commercial and non-commercial agricultural crops such as cotton, soybean and corn.

Currently, MON has a Zacks Rank 3 (Hold), but that could definitely change after the release of its first-quarter fiscal 2018 (ended November 2017) results. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.

We have highlighted some of the key stats from this just-revealed announcement below:

Earnings: MON reported adjusted earnings of 41 cents per share in first-quarter fiscal 2018 (on an ongoing basis), as against the Zacks Consensus Estimate of 38 cents per share.

Revenue: MON posted revenues of $2,658 million in first-quarter fiscal 2018, lower than the Zacks Consensus Estimate of $2,723 million.  

Key Factors: MON claimed that its pre-tax income would increase in fiscal 2018. The company perceives that improved glyphosate pricing and stronger demand for innovative crop yield enhancing solutions such as Intacta RR2 PRO soybeans will boost results in the quarters ahead.

MON anticipates to successfully close Bayer AG’s (BAYRY - Free Report) buyout deal by early 2018.   

Stock Price: At the time of writing, the stock price of MON was up nearly 0.05% ($0.06) in the pre-market trade on Nasdaq. Clearly the initial reaction to the release is positive. We perceive that the company’s better-than-expected earnings result has primarily driven the positive sentiment.

As of Jan 3, 2018, MON’s stock closed the trading session at $118 per share.  

Check back our full write up on this MON earnings report later!

Wall Street’s Next Amazon

Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.

Click for details >>
 


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Bayer Aktiengesellschaft (BAYRY) - free report >>

Published in